Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy (EOSCITPHO)

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Unknown; Phase 3

Conditions: Primary Hypertrophic Osteoarthropathy

Treatments: Drug: COX-2 inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT02438709

81170805，2008ZX09312-016

Details and patient eligibility

About

The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy

Full description

Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.

Enrollment: 30 estimated patients

Sex: All

Ages: 16 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosed with primary hypertrophic osteoarthropathy clinically
• over 16 years old
• no other medication intake
• informed consent signed

Exclusion criteria

• below 16 years old
• active gastric ulcer
• inflammatory bowel disease
• New York Heart Association classification（NYHA） II to IV
• liver or renal failure
• allergic to nonsteroid anti-inflammatory drugs
• not willing to participate

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

COX-2 Inhibitor

Experimental group

Description:

Patients who take COX-2 inhibitor

Treatment:

Drug: COX-2 inhibitor